

CE POSTER PRESENTATIONS

THURSDAY, OCT. 29
5:15-5:45P

		SCREEN
Improving Temperature Excursion Decision-Making for Specialty Oncology Medications Through Manufacturer Outreach	0.25 CE	1
Expanded Institutional Experience With Prophylactic Tocilizumab for Outpatient Bispecific Antibody Administration in Community Oncology	0.25 CE	2
Cutaneous Recurrence of Extramedullary Multiple Myeloma Within Surgical Scar Tissue	0.25 CE	3
Real-World Experience With Abatacept for Immune Checkpoint Inhibitor-Associated Myocarditis: Patient Characteristics and Hospital Outcomes	0.25 CE	4
Developing a Comprehensive Community-Based Bispecific Antibody Operations Program for Safe Step-Up Dosing and Ongoing Management	0.25 CE	5
Beyond Staffing Gaps: A Scalable Nursing Float Pool Model for Integrated Oncology Care	0.25 CE	6
Waste Not: How Drug Data Access Transforms Oncology Compounding Efficiency	0.25 CE	7
Implementing a Health-System-Wide Vial Optimization Initiative to Reduce Medication Waste and Improve Financial Stewardship	0.25 CE	8
From Triage to Teaching: Preparing Preceptors for What’s Next	0.25 CE	9
Implementation and Safety of an Outpatient Bispecific T-Cell Engager Program Within a Community Oncology Network	0.25 CE	10
Upcoming Medicare Part D Changes for 2027: What Oncology Practices Need to Know	0.25 CE	11
Healthcare Professional Perceptions of the Accuracy and Usability of Patient Education Sheets	0.25 CE	12
Oncology Optimized Limited Distribution: Real-World Pharmacist Feedback on Awareness, Workflow Integration, and Practice Change	0.25 CE	13
Glucagon-Like Peptide-1 Agonists and Breast Cancer Outcomes: Emerging Advancements in Metabolic Oncology	0.25 CE	14
Social Drivers of Health and Progression-Free Survival in Metastatic Breast Cancer Patients on Cyclin-Dependent Kinase 4/6 Inhibitors	0.25 CE	15
Optimizing Clinical Trial Workflow: Elevating the Role of the Pharmacy Technician Within Investigational Drug Services	0.25 CE	16
Circulating Tumor DNA as a Biomarker to Guide Treatment Escalation and De-Escalation in Non-Small Cell Lung Cancer: A Review of the Current Evidence	0.25 CE	17

Scan to Register & Earn CE

